BioNTech SE ADR Stock (US: Nasdaq) - BNTX
This is a German pharmaceutical company that broke out last year by producing a Covid vaccine along with Pfizer. They recently reported that they expect to continue to have revenue coming in from their Covid vaccine for at least the next year.
BNTX also has a large suite of other products both generating revenue now, and in their future pipeline. This was a successful company before Covid, but they were returning most of their profits into research and development.
Their stock buyback program is a sign that their management team is confident that they can continue to make profits after the vaccine windfall passes.
They also have several cancer drugs in their pipeline and a proven history of success in that market. Do not think of them as just a lucky winner in the vaccine race.
BioNTech is a leader in not just a mRNA vaccine maker, but also cancer research. They have some very promising drugs in their pipeline and have spent considerable resources on R&D in the past and will continue to earn a very handsome profit. It is underappreciated at the moment because investors think the easy Covid money has passed. Do not be fooled, you can be in this one for the long haul.
Leave a comment: